The WHO's Position on GLP-1 Drugs in Global Obesity Policy
The World Health Organization has weighed in on GLP-1 drugs' role in global obesity management, alongside concerns about access equity between wealthy and lower-income countries.
By the GLP Semaglutide editorial team · Last updated June 20, 2025
The World Health Organization doesn't approve or regulate individual drugs (that remains a national regulator function) but has published guidance and statements addressing GLP-1 drugs' potential role in global obesity and diabetes management, alongside broader public health strategy.
Access equity is a recurring theme
WHO and global health commentary has repeatedly raised concerns about GLP-1 drugs' high cost and concentrated availability in wealthy countries, questioning what a genuinely global public health response to obesity would require versus what current market dynamics are producing.
Not a substitute for national guidance
WHO statements inform but don't override national drug regulatory or health system decisions — actual access in any given country still depends on that country's own regulator and health system, as covered elsewhere in this section.
Primary sources